Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Chemotherapeutics in the treatment of multiple sclerosis.
Benzothiazole and stilbene derivatives as promising PET myelin radiotracers for multiple sclerosis.
American Society for Neurochemistry Annual Meeting
Prediction of oxygen uptake during walking in ambulatory persons with multiple sclerosis.
US and EU regulatory authorities accept PLEGRIDY™ (peginterferon beta-1a) marketing applications for review
Testing the measurement invariance of the University of Washington Self-Efficacy Scale short form across four diagnostic subgroups.
Are changes in gait and balance across the Disease Step Rating Scale in Multiple Sclerosis statistically significant and clinically meaningful?
Patient centered decision making: Use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices.
Our Products (page shows "Copaxone" as a trade name for glatiramer acetate)
Data supporting the role of Fyn in initiating myelination in the peripheral nervous system.
Site-Specific PEGylation Enhances the Pharmacokinetic Properties and Antitumor Activity of Interferon Beta-1b.
The Charcot Lecture | Beating MS: A story of B cells, with twists and turns.
Estrogen treatment in multiple sclerosis.
Interferon-beta(1b) treatment in neuromyelitis optica.
An Exploratory Investigation of Social Stigma and Concealment in Patients with Multiple Sclerosis.
Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS.
Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro.
Risks of immune system treatments.
Statement on a nonproprietary name adopted by the USAN Council
Genzyme provides update on U.S. LEMTRADA™ filing
The effects of teriflunomide on lymphocyte subpopulations in human peripheral blood mononuclear cells in vitro.
Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal function.
Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a ...
U.S. Patent Office Declares an Interference Between Forward Pharma and Biogen Regarding the Treatment of Multiple Sclerosis With 480 mg Daily Dose of DMF, the Active Ingredient in Tecfidera(R)
Use of interleukin-2 for management of natalizumab-associated progressive multifocal leukoencephalopathy: case report and review of literature.

Pages